We have also taken note of the claims1 of the association of mometasone DPI with a significantly lesser decrease in serum cortisol concentration area under the curve compared with the HFA-BDP, 200 μg MDI. The results seemed to show a numerically significant lack of cortisol suppression, but the results do not appear to be clinically significant. Given such small numbers of patients, it would seem appropriate to state the normal ranges of cortisol concentrations for all patients and then individually show the number of patients outside of the normal ranges and the degree to which they were outside of the normal ranges. For example, according to Table 2 in the article by Chrousos et al,1 the range at baseline for all patients was 998.1 to 4,286 nmol/L/24 h. The range for the HFA-BDP group at day 14 was 1,035 to 3,339 nmol/L/24 h. There was a 23% drop in the means from baseline to day 14, but all of the patients in the HFA-BDP group fell within the original normal baseline range. This hardly seems to be clinically significant, especially since there were no efficacy data given in this population. Thus, even if there was a clinically significant lack of a drop in cortisol with the mometasone DPI, the dose actually delivered to the patients was not shown to be efficacious in this study, whereas that dose of HFA-BDP has previously been shown to be efficacious.6–7 The assertions espoused by Chrousos et al,1 that DPIs demonstrate higher lung deposition than MDIs as well as the clinical significance of the lack of cortisol suppression, are therefore somewhat questionable.